This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Oncology, Other  • Radiation Therapy  • Drug Therapy  • Drug Therapy, Other  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

James L. Abbruzzese, MD

JAMA. 2008;299(9):1066-1067.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 2008, approximately 37 000 patients will be diagnosed with pancreatic adenocarcinoma in the United States, and most of these patients will succumb to this disease within the first year following diagnosis.¹ Only approximately 7400 patients will have localized cancer, usually involving the head of the pancreas, and are candidates for surgery if the tumor is resectable, as defined by the absence of vascular involvement.² Such patients are candidates for complete resection of the primary cancer. The prognostic significance of an incomplete resection is well-defined (ie, the survival duration of those who undergo an incomplete [R1] resection is on average shorter than that of patients achieving a complete [R0] resection and in some series is no different than the survival of patients with locally advanced stage III disease who receive chemoradiation without surgery, chemotherapy, or both).^3-4 With optimal patient selection, improved surgical techniques, and modern perioperative care, . . . [Full Text of this Article]

Author Affiliation: Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial
William F. Regine, Kathryn A. Winter, Ross A. Abrams, Howard Safran, John P. Hoffman, Andre Konski, Al B. Benson, John S. Macdonald, Mahesh R. Kudrimoti, Mitchel L. Fromm, Michael G. Haddock, Paul Schaefer, Christopher G. Willett, and Tyvin A. Rich
JAMA. 2008;299(9):1019-1026.
ABSTRACT | FULL TEXT